This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours

This study has been completed.
Information provided by:
Ipsen Identifier:
First received: May 15, 2006
Last updated: November 30, 2010
Last verified: November 2010
To evaluate, in patients with progressive neuroendocrine tumours who are not eligible to be treated with either surgery or chemotherapy at the moment of study inclusion, the efficacy of lanreotide Autogel in tumour growth stabilization.

Condition Intervention Phase
Neuroendocrine Tumours Drug: lanreotide (Autogel formulation) Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II, Open, Single Group, Multicentre Study to Evaluate the Efficacy and Safety of Lanreotide Autogel Administered Every 4 Weeks by Deep Subcutaneous Injection in the Tumour's Growth Stabilization of Patients With Progressive Neuroendocrine Tumours Who Are Not Eligible to be Treated With Either Surgery or Chemotherapy

Resource links provided by NLM:

Further study details as provided by Ipsen:

Primary Outcome Measures:
  • Time to disease progression (appearance of 1+ new lesions or increase >or= to 20% of sum of the longest diameters of target lesions compared to the lower sum of maximum diameters recorded since the start of the study). [ Time Frame: Month 3, 6, 9, 12, 15, 18, 21 and 24 ]

Secondary Outcome Measures:
  • To evaluate efficacy related to tumour's partial or total response, biological disease markers response, symptomatic control, effect of treatment on patient's quality of life [ Time Frame: Month 3, 6, 9, 12, 15, 18, 21 and 24 ]
  • Identify tumour growth stabilization predictive factors under treatment with lanreotide Autogel [ Time Frame: Month 3, 6, 9, 12, 18, 21 and 24 ]
  • Tolerance [ Time Frame: All visits ]

Enrollment: 30
Study Start Date: May 2006
Study Completion Date: November 2009
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: lanreotide (Autogel formulation)
120mg administered via deep subcutaneous injection every 28 days for up to 24 months or until disease progression.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patients with histopathologic diagnosis of well-differentiated neuroendocrine tumour or carcinoma according to WHO classification
  • patients who, according to RECIST criteria (Response Evaluation Criteria in Solid Tumours) present measurable disease
  • patients with progressive disease in the previous 6 months before their inclusion in the study
  • patients with positive IN111 octreotide scintigraphy

Exclusion Criteria:

  • patients with surgically removable localised disease
  • patients with progressive disease in the first six months of being diagnosed
  • patients with intestinal obstruction due to a carcinoid tumour
  • patients who have received treatment with somatostatin analogues during the 6 months before being included in the study
  • patients who have received treatment with radiotherapy, chemotherapy or interferon 4 weeks before being included in the study, or planned to receive these during the study
  • patients who have received treatment with liver artery embolisation or radiopharmaceuticals (endoradiotherapy) 12 weeks before being included in the study, or planned during the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00326469

H. Juan Canalejo
A Coruña, Spain, 15006
H. Virgen de los Lirios
Alcoy, Spain, 03804
H. General Univ. de Alicante
Alicante, Spain, 03010
H. Germans Trias i Pujol
Badalona, Spain, 08916
H. Santa Creu i Sant Pau
Barcelona, Spain, 08025
H. Clínic i Provincial
Barcelona, Spain, 08036
Corporación H. Parc Tauli
Barcelona, Spain, 08208
Consorci Sanitari de Terrassa
Barcelona, Spain, 08227
H. de Basurto
Bilbao, Spain, 48013
H. General de Elche
Elche, Spain, 03203
H. General de Hospitalet
Llobregat, Spain, 08906
H. de la Princesa
Madrid, Spain, 28006
H. Ramón y Cajal
Madrid, Spain, 28034
H. Clínico Univ. San Carlos
Madrid, Spain, 28040
H. 12 de Octubre
Madrid, Spain, 28041
H. Severo Ochoa
Madrid, Spain, 28911
Fundación H. Son Llàtzer
Palma de Mallorca, Spain, 07198
Consorcio H. de Pontevedre
Pontevedra, Spain, 36001
H. de Sagunto
Puerto de Sagunto, Spain, 46520
H. Clínico de Salamanca
Salamanca, Spain, 37007
Int. Oncológico San Sebastián
San Sebastián, Spain, 20012
H. Marques de Valdecilla
Santander, Spain, 39008
H. Univ. de Canarias
Tenerife, Spain, 38320
Hospital Universitario "Dr. Peset"
Valencia, Spain, 446017
H. La Fe
Valencia, Spain, 46009
H. Hospital General Universitario de Valencia
Valencia, Spain, 46014
H. Miguel Servet
Zaragoza, Spain, 50009
Sponsors and Collaborators
Study Director: Eva Pineda, MD Ipsen
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Eva Pineda, Ipsen Identifier: NCT00326469     History of Changes
Other Study ID Numbers: A-92-52030-166
Study First Received: May 15, 2006
Last Updated: November 30, 2010

Additional relevant MeSH terms:
Neuroendocrine Tumors
Carcinoid Tumor
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Neoplasms, Glandular and Epithelial
Antineoplastic Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on August 16, 2017